Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial-Reference-Cited by-同舟云学术

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Published:2014-07 Issue:8 Volume:15 Page:852-861
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ledermann Jonathan,Harter Philipp,Gourley Charlie,Friedlander Michael,Vergote Ignace,Rustin Gordon,Scott Clare L,Meier Werner,Shapira-Frommer Ronnie,Safra Tamar,Matei Daniela,Fielding Anitra,Spencer Stuart,Dougherty Brian,Orr Maria,Hodgson Darren,Barrett J Carl,Matulonis Ursula

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Cancer facts & figures 2013,2013

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

3. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

4. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities;Press;BMC Cancer,2008

5. Integrated genomic analyses of ovarian carcinoma;Nature,2011

Cited by 1239 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ovarian cancer in the Arab world: An updated review;Gene Reports;2024-12

2. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

3. Long-Term Survival in BRCA1 Mutant Advanced Ovarian Cancer: Unveiling the Impact of Olaparib;Diagnostics;2024-08-29

4. GUIDANCE: eine prospektive, biomarkerstratifizierte Phase-II-Studie zur PARP-Inhibition im kleinzelligen Lungenkarzinom;Forum;2024-08-28

5. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models;Genome Medicine;2024-08-26